Advancements in the Treatment of CLL: The Rise of Zanubrutinib as a Preferred Therapeutic Option
Ibrutinib, the first-in-class Bruton’s tyrosine kinase inhibitor (BTKi), is a commonly deployed therapeutic option for previously untreated and relapsed/refractory (R/R) patients with chronic lymphocytic leukemia (CLL). The use of ibrutinib is, however, partially limited by off-target side effects....
Main Authors: | Stefano Molica, Constantine Tam, David Allsup, Aaron Polliack |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2023-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/15/14/3737 |
Similar Items
-
Treatment of relapsed/refractory chronic lymphocytic leukemia with Zanubrutinib after progressing on other BTK inhibitors
by: Nkolika Nwankwo, et al.
Published: (2024-01-01) -
Zanubrutinib in patients with treatment‐naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded‐access study of 50 patients in the United States
by: Jorge J Castillo, et al.
Published: (2023-02-01) -
Current Treatment Options in CLL
by: Moritz Bewarder, et al.
Published: (2021-05-01) -
Zanubrutinib-induced petechial ecchymotic reaction in a previously irradiated area in a patient with chronic lymphocytic leukemia
by: Serena M. Vilasi, BS, et al.
Published: (2024-04-01) -
Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
by: Anna Wolska-Washer, et al.
Published: (2023-03-01)